Oncoc4
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9640 Medical Center Dr, Rockville, Maryl...Website
www.oncoc4.comRevenue
$28.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Oncoc4
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases.Explore more
Oncoc4 Org Chart
Get the full picture
Sign in to uncover key details.
SP
Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncoc4 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Oncoc4, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oncoc4 has new funding data
Click to see if Oncoc4 had a recent Job posting/layoffs
Check if Oncoc4 has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Oncoc4 recently announced quarterly report
Check out if Oncoc4 is spiking on competitors!
Product Launch: Get notified when Oncoc4 launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Oncoc4
Recommended Actions
Reach out to Masked Content who joined Oncoc4 as Masked Content
Find 2 more new buyers
Compare Similar Companies to Oncoc4
Compare insights from companies similar to Oncoc4, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oncoc4 is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oncoc4 is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oncoc4.
Oncoc4 financials insights
Gather financial insights about Oncoc4, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$50M
Oncoc4 Tech Stack
A closer look at the technologies used by Oncoc4
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Oncoc4 News & Media
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785) and in China (CTR20253261) Fast Track Designation Supports Expedited Development of Cesalatamig for Non-small Cell Lung Cancer (NSCLC) that Progressed after Concurrent or Sequential PD-(L)1-targeted Immunotherapy and Platinum-based Chemotherapy ROCKVILLE, Md., Sept. 16, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTOncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of legal, intellectual property, corporate, and strategic experience across biotechnology, global pharmaceutical companies, private practice, and scientific research. Prior to joining OncoC4, Dr. Chen served asOncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced dosing of the first patient following the clearance of the Investigational New
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Oncoc4
Sign Up For FreeTo access detailed company insights
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immun... Read More
